Chi-Med announced that it has submitted an application for the marketing of a new drug in the US for the treatment of MET-driven EGFR mutant lung cancer in combination with Teresa.

Zhitongcaijing · 2d ago
Chi-Med announced that it has submitted an application for the marketing of a new drug in the US for the treatment of MET-driven EGFR mutant lung cancer in combination with Teresa.